Advanced in RUNX1 Familial Platelet Disorder

Dr. Ralph V. Boccia

Hematology Oncology | Oncology | Hematology
American Oncology Partners PA
6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Advanced in RUNX1 Familial Platelet Disorder
American Oncology Partners PA
6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ralph Boccia is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Boccia is rated as an Advanced provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. His top areas of expertise are Bone Tumor, Anemia, Iron Deficiency Anemia, Multiple Myeloma, and Splenectomy. Dr. Boccia is currently accepting new patients.

His clinical research consists of co-authoring 71 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
Suburban Hospital
Sibley Memorial Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

AMERICAN ONCOLOGY PARTNERS PA
6410 Rockledge Dr, Suite 660, Bethesda, MD 20817
Other Locations
AMERICAN ONCOLOGY PARTNERS PA
106 Irving St Nw, Suite 4100, Washington, DC 20010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
Enrollment Status: Recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drugs: Glufosfamide, Fluorouracil
Study Phase: Phase 3
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Enrollment Status: Completed
Publish Date: August 21, 2025
Intervention Type: Drug
Study Drugs: Parsaclisib, Hexal, Gazyvaro
Study Phase: Phase 1
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drugs: TAK-079, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Biological
Study Drug: Descartes 11
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Study Phase: Phase 1/Phase 2
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug
Study Drug: Crofelemer [Mytesi]
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing
A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing
Enrollment Status: Completed
Publish Date: October 13, 2017
View 25 Less Clinical Trials

71 Total Publications

A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Journal: Targeted oncology
Published: March 04, 2024
Similar Doctors
Distinguished in RUNX1 Familial Platelet Disorder
Dr. Paul A. Bannen
Hematology Oncology | Oncology
Distinguished in RUNX1 Familial Platelet Disorder
Dr. Paul A. Bannen
Hematology Oncology | Oncology

Rcca MD LLC

18111 Prince Philip Dr, 
Olney, MD 
 (9.9 miles away)
301-774-6136
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Paul Bannen is a Hematologist Oncology specialist and an Oncologist in Olney, Maryland. Dr. Bannen is rated as an Advanced provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. His top areas of expertise are Paris-Trousseau Thrombocytopenia, RUNX1 Familial Platelet Disorder, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Bannen is currently accepting new patients.

Advanced in RUNX1 Familial Platelet Disorder
Dr. William A. Houck
Hematology Oncology | Hematology | Oncology
Advanced in RUNX1 Familial Platelet Disorder
Dr. William A. Houck
Hematology Oncology | Hematology | Oncology

Johns Hopkins University

5759 Cedar Ln, 
Columbia, MD 
 (18.7 miles away)
443-718-3738
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Houck is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Houck is rated as a Distinguished provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). Dr. Houck is currently accepting new patients.

Advanced in RUNX1 Familial Platelet Disorder
Dr. Nicholas J. Farrell
Hematology Oncology | Oncology | Hematology
Advanced in RUNX1 Familial Platelet Disorder
Dr. Nicholas J. Farrell
Hematology Oncology | Oncology | Hematology

Maryland Oncology Hematology PA

7350 Van Dusen Rd, Suite 370, 
Laurel, MD 
 (14.3 miles away)
301-982-9800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicholas Farrell is a Hematologist Oncology specialist and an Oncologist in Laurel, Maryland. Dr. Farrell is rated as a Distinguished provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. His top areas of expertise are Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Iron Deficiency Anemia. Dr. Farrell is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boccia's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 31 Advanced Conditions
    View All 81 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile